Clemondo Group (CLEM) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
20 Aug, 2025Executive summary
Net sales increased by 9% year-over-year to 73.0 MSEK in Q2 2025, with all market areas except contract manufacturing contributing to growth.
EBITDA reached 4.3 MSEK, but excluding one-time CEO transition costs, adjusted EBITDA was 7.4 MSEK with a margin of 10.1%.
Profit after tax was 0.0 MSEK, compared to 0.9 MSEK in Q2 2024.
CEO transition completed, with Peter Andersson appointed as new CEO effective by February 2026.
Financial highlights
Net sales: 73.0 MSEK (66.8 MSEK Q2 2024), up 9% year-over-year.
EBITDA: 4.3 MSEK (5.5 MSEK Q2 2024); adjusted EBITDA: 7.4 MSEK.
EBIT: 0.7 MSEK (1.8 MSEK Q2 2024); EBIT margin: 0.9%.
Earnings per share: 0.00 SEK (0.06 SEK Q2 2024).
Cash flow from operations before working capital changes: 5.4 MSEK (3.2 MSEK Q2 2024).
Outlook and guidance
Growth initiatives in digitalization, logistics, and product assortment are expected to support continued profitable growth.
Short-term profit margins may be pressured by ongoing investments.
The company aims for at least 12% annual growth and an EBITDA margin of at least 10% over a business cycle.
Latest events from Clemondo Group
- Q4 2025 saw 11% sales growth, margin pressure from investments, and strong Medical Care gains.CLEM
Q4 202526 Feb 2026 - Q3 2025 saw 13% sales growth and strong segment performance, but lower margins due to investments.CLEM
Q3 202511 Nov 2025 - Q3 2024 saw stable earnings, strong equity, and growth in Hygien and Industri amid a weak market.CLEM
Q3 202413 Jun 2025 - Sales declined but gross margin and financial position improved, with growth in Hygiene and Industry.CLEM
Q2 202413 Jun 2025 - Q1 2025 saw 12% sales growth, margin expansion, and Medical Care emerge as a key growth driver.CLEM
Q1 20256 Jun 2025 - Hygiene and Industry growth offset Vehicle weakness, with strong equity and new contracts for 2025.CLEM
Q4 20245 Jun 2025